About – Douglas Berger Psychiatrist Tokyo


Dr. Douglas Berger, M.D., Ph.D., Meguro Counseling Center Director

Dr. Berger came to Japan as a medical exchange student and psychiatric researcher at the Tokai University School of Medicine on a research fellowship from the Matsumae International Foundation. He later returned to Japan to do further psychiatric research at the Tokyo University Department of Psychosomatic Medicine and the Tokyo Institute of Psychiatry. Dr. Berger speaks native-level Japanese and regularly conducts psychotherapy for mixed-cultural couples as well as the local Japanese community. This page lists Dr. Berger’s research activity, and this page is an archive of community education articles for the Tokyo Families Magazine written by Dr. Berger. Dr. Berger also works extensively with children as Director of the Tokyo Child & Adolescent Counseling Service. Dr. Berger is a legal permanent resident of Japan.

Douglas Berger is a now a fully bilingual American board certified psychiatrist, is the Director of the Tokyo Meguro Counseling Center. Douglas Berger is a M.D., and a Ph.D. Dr.  Berger is a graduate of New York Medical College where he completed a 4-year residency program in psychiatry. He then finished a fellowship in Psychosomatic Medicine at the Albert Einstein College of Medicine. Now based in Tokyo, he had served on the Faculty of the Albert Einstein College of Medicine Department of Psychiatry in New York as an Assistant Professor of Psychiatry and licensed practicing U.S. physician. Dr. Berger’s Japanese qualifications include a Ph.D. from the University of Tokyo School of Medicine received for psychiatric research done while at the Tokyo University Department of Psychosomatic Medicine.

Credential Verifications

Dr. Berger’s medical degree is from the United States, he is well-versed in the use of psychiatric medication and can guide the use of psychiatric medications integrated with psychotherapy through the physicians affiliated with his counseling practice (he does not directly practice medical care in Japan). Further information on Dr. Berger can be seen on his personal home page.

Publications by Dr. Douglas Berger, psychiatrist in Tokyo

Berger D: DOUBLE BLINDING REQUIREMENT FOR VALIDITY CLAIMS IN COGNITIVE-BEHAVIORAL THERAPY INTERVENTION TRIALS FOR MAJOR DEPRESSIVE DISORDER. Analysis of Hollon S, et al., Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, F1000Research 2015, 4:639 (doi: 10.12688/f1000research.6954.1). U.S. National Library of Medicine version.

Berger D: DOUBLE-BLINDING AND BIAS IN MEDICATION AND COGNITIVE-BEHAVIORAL THERAPY TRIALS FOR MAJOR DEPRESSIVE DISORDER, F1000Research 2016, 4:638 (doi: 10.12688/f1000research.6953.2). U.S. National Library of Medicine version.

Articles by Douglas Berger, M.D., Ph.D. for Tokyo Families magazine.

Click here to see a full list of articles.

For more information on Dr. Doug Berger, read some of the articles here.

To contact Douglas Berger psychiatrist Tokyo and set up an appointment, click here.

ADHD is both over- and under-diagnosed, depending on the set of people you look at: https://t.co/wNPdlFMiUd The authors’ title “Are We Overdiagnosing and Overtreating ADHD?”, is somewhat unfair to the cohort of persons who are underdiagnosed. https://t.co/sJUSXfRv1G

Cold water swimming for depression https://t.co/rBHqTJW7bF What % and which depressives might benefit, is there placebo effect, what temp, duration, frequency is best is still unclear, & if this is reducing inflammation or stress response is conjecture. https://t.co/2opApRuwKL

There is confusion in depression with “full-remission” (no-symptoms), “effective” (defined at each use), and "responsive" (50% improvement) https://t.co/8g5BXeBjET Many trials claim efficacy using "responsive" but "responsive" is easy to achieve. Us: https://t.co/uZEIPRxr0J

Is there a list of CBT clinical trials for anxiety or depressive disorders that have had subject blinding or subject+treater blinding, or blind placebo? Rater blinding (often mistakenly called single-blind) is not so valuable as blind raters just record what the subject reports.

Funding longer GP consults seems ineffective for patients who are dead-set to get antibiotics. Funding public ads campaign, removing prescription repeats, and reducing prescription expiry to between 2 weeks and 3 months as noted in the article seems the way to go.

Load More...

Some mistakenly think tramadol is a combination drug with both an opioid and an SNRI: https://t.co/kYtNeXyy9x Tramadol has a dual mechanism of action but it is not a combination drug. https://t.co/vhEwPF9JpC

Farah’s book on Hemingway had no interview & he/his estate gave no consent https://t.co/7y5FAs4cvY There's no brain scan/autopsy. Farah does not prove chronic traumatic encephalopathy nor disprove bipolar disorder. The estate may sue after sales grow. https://t.co/1HKbrH9Y6i #li

NIDA instills pot fear in doctors as causing schizophrenia & statements like "use and possession of cannabis is illegal in under federal law" etc: https://t.co/9LKyC7PDrw. Dr. Kosten is NIDA-sponsored & Psychiatric Times known to publish NIDA articles. https://t.co/vhEwPF9JpC #li

Questionable ethics when psychiatrists label persons they did not examine, here deceased poet Robert Lowell: https://t.co/KsJ2H0XRZE Psychiatric conditions are not provable so that (re)labeling Mr. Lowell is concerning even if his doctors did so. https://t.co/RZFx8zOZJO #li

Blue-blocking glasses for mania? https://t.co/vmAOFTUtGb only 11-12 subjects in each group in a single blind (not double-blind) study, only followed for one week. Poorly controlled studies should not have results exaggerated. https://t.co/lABkWI4nXZ

Load More...